Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data

Core Insights - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is identified as one of the most undervalued stocks on NASDAQ, with an Overweight rating and a price target of $147 set by Piper Sandler in anticipation of upcoming clinical trial data [1][2] Group 1: Company Overview - Jazz Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious illnesses, with key products including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos [3] Group 2: Clinical Trials and Market Potential - The company is preparing to report progression-free survival data from its HERIZON-GEA-01 study in Q4 2025, which evaluates zanidatamab as a first-line therapy for advanced/metastatic gastroesophageal adenocarcinoma [1] - Piper Sandler held a webinar with an oncologist to discuss potential trial outcomes, suggesting that favorable results could allow zanidatamab to capture a significant share of the treatment market [2]